HC Wainwright & Co. Maintains Buy on FibroBiologics, Lowers Price Target to $6

Benzinga · 2d ago
HC Wainwright & Co. analyst Matthew Caufield maintains FibroBiologics (NASDAQ:FBLG) with a Buy and lowers the price target from $8 to $6.